Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Biochim Biophys Acta ; 1401(2): 195-202, 1998 Feb 04.
Artículo en Inglés | MEDLINE | ID: mdl-9531975

RESUMEN

Glomerular capillary pressure is involved in the development of chronic renal failure and has at least two effects on mesangial cells: transmembrane hydrostatic pressure and stretch. To clarify whether pure hydrostatic pressure itself affects the proliferation of cultured rat mesangial cells, we compared the cell number under atmospheric pressure condition with high pressure condition. At 24 and 48 h with 0.5% serum, cell number was significantly higher under high pressure condition than under atmospheric pressure condition. At 48 h, cell number under high pressure condition was increased in a pressure-dependent manner. Furthermore, flow cytometric assay indicated that pressure-load could promote DNA synthesis rate at S phase and enhance G1/S progression induced by low concentration of serum (0.5%). These results suggest that pure hydrostatic pressure itself can promote the proliferation of cultured rat mesangial cells by advancing cell cycle progression in vitro.


Asunto(s)
Presión Sanguínea/fisiología , Mesangio Glomerular/citología , Presión del Aire , Animales , Bromodesoxiuridina/metabolismo , Capilares , Dióxido de Carbono/farmacología , División Celular/fisiología , Tamaño de la Célula/fisiología , Medios de Cultivo Condicionados/farmacología , Medio de Cultivo Libre de Suero/farmacología , ADN/análisis , Citometría de Flujo , Colorantes Fluorescentes , Fase G1/fisiología , Mesangio Glomerular/fisiología , Glomérulos Renales/irrigación sanguínea , Masculino , Oxígeno/farmacología , Ratas , Ratas Wistar , Fase S/efectos de los fármacos , Fase S/fisiología , Factores de Tiempo
2.
Hypertension ; 33(4): 975-80, 1999 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10205233

RESUMEN

The aim of this study was to clarify the differences between the angiotensin II type 1 (AT1) receptor antagonist and the angiotensin-converting enzyme (ACE) inhibitor on smooth muscle and nonmuscle myosin heavy chain isoforms in aortic smooth muscle cells of Wistar-Kyoto rats and spontaneously hypertensive rats. All 4 myosin heavy chain isoforms are heterogeneously expressed in the smooth muscle cells of the aortic tunica media in 20-week-old rats, and the contractile-type myosin heavy chains are highly expressed in smooth muscle cells of the aortic tunica media compared with the synthetic-type myosin heavy chains. Both the AT1 receptor antagonist and the ACE inhibitor had the same effects on hemodynamics, smooth muscle cell hypertrophy and proliferation, fibrosis, and vascular remodeling in spontaneously hypertensive rats. However, the AT1 receptor antagonist had a more potent effect on the downregulation of the synthetic-type myosin heavy chains than the ACE inhibitor in spontaneously hypertensive rat aortic tunica media. In contrast, these effects of the AT1 receptor antagonist and the ACE inhibitor on hemodynamics, morphology, fibrosis, and expression of myosin heavy chain isoforms in smooth muscle cells of the aortic tunica media were not observed in Wistar-Kyoto rats. Thus, within 6 weeks, the AT1 receptor antagonist might modulate the cellular composition of myosin heavy chain isoforms in smooth muscle cells more efficiently than the ACE inhibitor, without morphological changes in the spontaneously hypertensive rat aorta.


Asunto(s)
Antagonistas de Receptores de Angiotensina , Aorta/efectos de los fármacos , Hipertensión/metabolismo , Cadenas Pesadas de Miosina/análisis , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Animales , Aorta/química , Peso Corporal/efectos de los fármacos , Regulación hacia Abajo , Hemodinámica/efectos de los fármacos , Hipertensión/patología , Hipertensión/fisiopatología , Inmunohistoquímica , Masculino , Músculo Liso Vascular/química , Músculo Liso Vascular/efectos de los fármacos , Isoformas de Proteínas/análisis , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY
3.
Cell Prolif ; 33(1): 19-28, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10741641

RESUMEN

The direct effects of the nucleoside transporter inhibitor dilazep on the cell cycle of mesangial cells have not before been investigated. The purpose of this study was to elucidate whether dilazep can inhibit the proliferation of mesangial cells and how it interferes with the cell cycle of these cells. DNA histograms were used and BrdUrd uptake rate was measured by flow cytometry. There was no significant difference in the cell numbers among the untreated group and the 10(-5) M, 10(-6) M or 10(-7) M dilazep-treated groups at 24 h of incubation. However, at 48 and 72 h, the cell numbers in the dilazep-treated groups were significantly lower compared with that of the untreated group (P < 0.005). The DNA histograms of cultured rat mesangial cells at 12, 24, and 48 h of incubation with 10(-5) M dilazep showed that the ratio of the S phase population in the dilazep-treated group decreased by 2.2% at 12 h, by 9.6% at 24 h, and by 18.9% at 48 h compared with the untreated group. The ratio of the G0/G1 phase population in the dilazep-treated group significantly increased: 6.8% at 12h (P < 0.05), 13.9% at 24 h (P < 0.001), and 76.5% at 48 h (P < 0.001) compared with the untreated group. A flow cytometric measurement of bivariate DNA/BrdUrd distribution demonstrated that the DNA synthesis rate in the S phase decreased after 6 h (P < 0.005) and 12 h (P < 0.05) of incubation compared with the untreated group. These results suggest that dilazep inhibits the proliferation of cultured rat mesangial cells by suppressing the G1/S transition by prolonging G2/M and through decreasing the DNA synthesis rate.


Asunto(s)
Proteínas Portadoras/antagonistas & inhibidores , Ciclo Celular/efectos de los fármacos , ADN/biosíntesis , Dilazep/farmacología , Mesangio Glomerular/citología , Mesangio Glomerular/efectos de los fármacos , Proteínas de la Membrana/antagonistas & inhibidores , Animales , Bromodesoxiuridina/metabolismo , División Celular/efectos de los fármacos , Citometría de Flujo , Mesangio Glomerular/metabolismo , Técnicas In Vitro , Cinética , Masculino , Proteínas de Transporte de Nucleósidos , Nucleósidos/metabolismo , Ratas , Ratas Wistar , Fase S/efectos de los fármacos
4.
Clin Nephrol ; 55(3): 238-42, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11316245

RESUMEN

AIMS: It has been suggested that angiotensin II (Ang II) promotes hypertrophy and hyperplasia of mesangial cells. Nonmuscle myosin heavy chain-B (NMHC-B) and alpha-smooth muscle (SM) actin are considered to be molecular markers for phenotypic change ofproliferative mesangial cells. One of the clinical characteristics in Gitelman's syndrome (GS) is the elevation of plasma Ang II. However, little is known about the relation between Ang II and phenotypic change of mesangial cells in patients with GS. In this report, we examined the expression of NMHC-B and alpha-SM actin in mesangial cells of two GS patients. MATERIALS AND METHODS: Plasma renin activity, and the concentrations of Ang II, 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha), urinary kallikrein, and 6-keto-PGF1alpha were measured. Immunohistochemical staining of NMHC-B and alpha-SM actin in mesangial cells of GS patients was also performed. RESULTS: Both cases of GS showed normal glomerular function, few histological abnormalities, and higher than normal plasma concentrations of renin and Ang II. Furthermore, one case showed a high urinary concentration of kallikrein and the expression of both NMHC-B and alpha-SM actin in mesangial cells. The other case showed a high urinary concentration of 6-keto-PGF1alpha but not kallikrein and without the expression of NMHC-B and alpha-SM actin. CONCLUSION: Not only plasma kinin-kallikrein and prostaglandins, but the renal expression of NMHC-B and alpha-SM actin may be variable in different patients with GS.


Asunto(s)
Alcalosis/metabolismo , Calcio/orina , Mesangio Glomerular/química , Hipopotasemia/metabolismo , Magnesio/sangre , Cadenas Pesadas de Miosina/análisis , Simportadores , Actinas/análisis , Adulto , Aldosterona/sangre , Proteínas Portadoras/genética , Femenino , Humanos , Hipopotasemia/genética , Inmunohistoquímica , Sistema Calicreína-Quinina , Masculino , Persona de Mediana Edad , Mutación , Miosina Tipo IIB no Muscular , Renina/sangre , Simportadores del Cloruro de Sodio , Síndrome
6.
J Biol Chem ; 273(27): 16905-12, 1998 Jul 03.
Artículo en Inglés | MEDLINE | ID: mdl-9642252

RESUMEN

Progressive renal diseases lead to prolonged glomerular hypertension, which induces the proliferation of mesangial cells. This proliferation is thought to be involved in the development of renal injury. Here we investigate mitogen-activated protein kinase (MAPK) activation and cell proliferation in mesangial cells under conditions of high pressure. After pressure-load, the phosphorylation level of MAPK (at Tyr-204) increases rapidly with a peak at 1 min, although the amount of MAPK remains almost constant during pressure-load. To confirm the activation of MAPK, we carried out an immunoprecipitation-kinase assay. MAPK activity during pressure-load shows kinetics similar to that of the tyrosine phosphorylation. In contrast, c-Jun N-terminal kinase 1 (JNK1) phosphorylation falls below basal levels in response to high pressure. Immunocytochemical observations show phosphorylated MAPK in the nucleus at 10 min. The expression of c-Fos, a nuclear transcription factor, is induced by high pressure, and the induction is significantly inhibited by PD98059 (50 microM), an upstream MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitor of MAPK. The expression of the c-Jun that is induced by JNK1 activation remains unchanged during pressure-load. MAPK phosphorylation and cell proliferation by applied pressure are significantly inhibited by genistein, a tyrosine kinase inhibitor in a dose-dependent manner, but not by protein kinase C inhibitors, chelerythrine and GF109203X. Genistein also blocks pressure-induced tyrosine phosphorylation of proteins with molecular masses of 35, 53, and 180 kDa. To clarify the physiological role in MAPK activation under high pressure conditions, we transfected antisense MAPK DNA into mesangial cells. The antisense DNA (2 microM) inhibited MAPK expression by 80% compared with expression in the presence of sense or scrambled DNA, and significantly blocked pressure-induced cell proliferation. Treatment of cells with MEK inhibitor also produced a similar result. MEK inhibitor strongly suppresses DNA synthesis induced by pressure-load. Cyclin D1 expression is significantly increased under high pressure conditions, and the increase is blocked by treatment with MEK inhibitor. These findings show that pressure-load, a novel activator of MAPK, induces the activation of tyrosine kinases, and enhances the proliferation of mesangial cells, probably through cyclin D1 expression.


Asunto(s)
Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , División Celular , Mesangio Glomerular/enzimología , Animales , Secuencia de Bases , Cartilla de ADN , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Mesangio Glomerular/citología , Fosforilación , Presión , Ratas , Especificidad por Sustrato
7.
Nephron ; 88(2): 134-7, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11399915

RESUMEN

Appropriate dosing of pilsicainide hydrochloride, an anti-arrhythmic drug excreted via the kidney, was investigated in patients on dialysis. Ten chronic hemodialysis patients with coexisting severe palpitation of supraventricular premature contractions (SVPC) were treated with 25 mg of pilsicainide hydrochloride before dialysis. All of their plasma concentrations were maintained within the therapeutic range and their mean dialysis rate was 32%. After 2 weeks, 7 patients were followed with consecutive daily dose treatment. In 3 of them, the dosage was returned to the single pre-dialysis administration because of the elevated plasma concentration reaching the toxic range 1 month after the start of administration. The dose schedule was maintained, and plasma pilsicainide concentrations remained within the therapeutic range during the 6-month follow-up. No abnormal findings were found in any parameters of electrocardiography, echocardiography or biochemistry. The number of SVPC diminished > 90% compared to the pretreatment level.


Asunto(s)
Antiarrítmicos/administración & dosificación , Lidocaína/análogos & derivados , Lidocaína/administración & dosificación , Diálisis Renal , Antiarrítmicos/sangre , Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/complicaciones , Arritmias Cardíacas/tratamiento farmacológico , Complejos Atriales Prematuros/tratamiento farmacológico , Complejos Atriales Prematuros/fisiopatología , Ecocardiografía , Electrocardiografía Ambulatoria , Femenino , Humanos , Fallo Renal Crónico/complicaciones , Lidocaína/sangre , Lidocaína/uso terapéutico , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA